BMY Stock UPDATES Bristol-Myers Squibb Company (BMY) 58.19 11/02/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 2, 2014 at 8:53 PM

Bristol-Myers Squibb Company (BMY) 58.19 $BMY

Final Glance: Pharmaceuticals companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)

Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.18 (-0.65), AGN: 190.06 (+0.62), ACT: 242.74 (-0.47), BMY: 58.19 (-0.79)

Midday Glance: Pharmaceuticals companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)

Early Glance: Pharmaceuticals companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)

Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks
at The Street - Fri Oct 31, 9:54AM CDT
Remember these franchises and who captains them.
AGN: 190.06 (+0.62), MMM: 153.77 (+1.67), CMG: 638.00 (-1.68), BMY: 58.19 (-0.79)

AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)

Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:39AM CDT
Bristol-Myers Squibb Company (BMY) was a big mover last session, as its shares rose nearly 9% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ILMN: 192.58 (-0.84), BMY: 58.19 (-0.79)

Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.77 (+1.67), BIIB: 321.08 (+0.08), HON: 96.12 (+0.53), FB: 74.99 (+0.88), BMY: 58.19 (-0.79), MGM: 23.25 (+0.27), ATK: 116.96 (+6.77), YRCW: 21.44 (+3.24), UPS: 104.91 (+1.62), SLB: 98.66 (+1.04), CELG: 107.09 (+0.15), WPRT: 6.17 (+0.12), SBUX: 75.56 (-1.76), TTWO: 26.45 (+1.18), DO: 37.71 (-0.94), ETP: 64.43 (+0.41), GILD: 112.00 (-2.22), ARR: 3.96 (-0.01), CMG: 638.00 (-1.68), MPEL: 27.14 (+0.78), WNC: 10.30 (+0.81), CRL: 63.16 (+0.35), AAPL: 108.00 (+1.02), REGN: 393.72 (+0.92)

Lung cancer drug promising
at Investor's Business Daily - Thu Oct 30, 6:14PM CDT
Bristol-Myers Squibb (BMY) reported good midstage trial results for its drug candidate Opdivo in advanced squamous-cell lung cancer, boosting its share price. The drugmaker said that a year after the treatment, 41% of patients were still alive;...
BMY: 58.19 (-0.79)

Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)

Most active New York Stock Exchange-traded stocks
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KO: 41.88 (+0.48), AVP: 10.40 (+0.43), F: 14.09 (+0.14), GE: 25.81 (+0.14), ABX.TO: 13.38 (-0.37), ABX: 11.87 (-0.42), PFE: 29.95 (+0.11), BAC: 17.16 (+0.13), BMY: 58.19 (-0.79), RAD: 5.25 (+0.07), AA: 16.76 (+0.54), YRI.TO: 4.49 (-0.50), S: 5.93 (-0.07), TWTR: 41.47 (-0.33), AUY: 3.98 (-0.48)

Bristol-Myers Squibb (BMY) Stock Is Gaining on Positive Phase 2 Results
at The Street - Thu Oct 30, 1:30PM CDT
Bristol-Myers Squibb (BMY) shares are climbing after its lung cancer treatment showed positive phase 2 test results.
BMY: 58.19 (-0.79)

Big Pharma Solid Q3 Earnings Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - ZACKS - Thu Oct 30, 1:00PM CDT
Pharma ETFs have been surging over the past one week buoyed by solid earnings from big industry players.
IHE: 145.99 (-0.68), JNJ: 107.78 (+0.74), PPH: 63.38 (+0.22), PJP: 68.69 (+0.02), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)

Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
Business Wire - Thu Oct 30, 12:00PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.
BMY: 58.19 (-0.79)

Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers
PR Newswire - Thu Oct 30, 11:45AM CDT
Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed. Abilify is also one of the most preferred branded antipsychotics relative to other branded antipsychotics, according to surveyed managed care organization (MCO) medical director/pharmacy directors (MDs/PDs). The findings also reveal that the majority of surveyed psychiatrists perceive current antipsychotics to be only somewhat effective in reducing negative or cognitive symptoms of schizophrenia. Among emerging agents that were profiled, encenicline (Forum Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma) garnered the greatest expected patient share from surveyed psychiatrists, if the drug were to be reimbursed on a favorable tier for the treatment of cognitive impairment associated with schizophrenia (CIAS).
BMY: 58.19 (-0.79)

Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Michaels' Report: Holiday Season Trends in 2026

Making the Holidays Personal: A New Shift As holiday lights flicker on in neighborhoods across the country, what's lighting up more than just front yards this year is a shift in consumer desires. The 2026 Michaels State of the Holiday Season Report, crafted meticulously with Morning Consult, reveals some trends that just might shake up how folks celebrate this year....

Celsius Faces Class Action for Misleading Investors

Navigating the Legal Storm Here we go again, folks — another big name, Celsius Holdings Inc. (NASDAQ: CELH), finds itself under the microscope with a lawsuit looming over accusations of securities law violations. Seems like CELH shareholders are in for a bumpy ride as the DJS Law Group pushes forward with a class action, all due to some eyebrow-raising business with...

PAG Secures $355M to Accelerate Aggressive Growth

Platform Accounting's Bold Expansion Move When you hear about a $355 million strategic financing round, it paints a picture of company ambitions colored in big, bold strokes. Platform Accounting Group (PAG) has managed to secure such a hefty financial backing from Treville Capital Group, taking a serious shot at expanding its footprint and offerings. This is no small...

Hemlo Mining's Q3 2026: Challenges and New Solutions

Resilience in the Face of Operational Setbacks Here's a peek into Hemlo Mining's latest exploits. They're riding a rollercoaster of operational challenges, yet still managing to chug along with stable gold production. It's like trying to drive uphill with a flat tire, but somehow, Hemlo's trucking along without missing too much of a beat. The numbers are in, and despite a...

Renue's Skincare Study: Promising Results on Aging Skin

A New Chapter in Skin Aging Research Here's a twist in the skincare narrative you probably weren't expecting—someone's finally paying attention to aging body skin. Cue the applause for Renue By Science, the folks who released a new white paper uncovering positive findings on their Renue Blue Moisturizing Body Cream. Ignoring the usual fixation on facial creams, this...

Volkswagen Leads Charge in AI-Driven AV Development

Volkswagen's Bold Move into AI for AVs Volkswagen's really cranking the gears on the autonomous vehicle (AV) scene. They’re weaving AI into the mix like no tomorrow. What’s cooking here is their new data flywheel driven by Porsche and partnerships with heavy hitters like NVIDIA and Microsoft. The move aims to cut back on endless test drives and push AV development...

Longitude Health Strengthens Ranks with Chris Shea Hire

New Leadership for Longitude Health's Legal Team Longitude Health's recent appointment of Chris Shea as Chief Legal and Administrative Officer might not make immediate waves in stock circles, but if you've been paying attention to healthcare's convoluted growth dance, you'd see the stakes. Shea's been knee-deep in the nitty-gritty of the health system labyrinth for more...

SEC Enforcement Lags: FY26 Sees Subdued Activity Surge

Parsing the Numbers: SEC's FY26 Performance It's like watching paint dry in the middle of a trading frenzy; the SEC's enforcement actions in FY26 were nothing to write home about. A mere 308 enforcement actions graced the ledger, a stunning 57% dive below the average from FY18 through FY25. When you think about the established numbers, it feels like the SEC decided to...

Teleste Unveils AI-Enhanced Rail Info Platform Innovation

A Shake-Up in Rail Passenger Information Now, here's something from left field that might just have people paying attention while on the go. Teleste, a Finnish company, just put out a gem in rail passenger information systems with the introduction of Acapela's AI-based voice tech into their S-ARRIVE platform. Picture clearer, more natural announcements for every stop,...

TrewUp Scores Another Inc. Power Partner Award Win

Breaking Through the Noise in B2B Nobody today would be shocked to hear business owners are practically drowning in options when it comes to B2B service providers. But amid this noisy sea, TrewUp has managed to shout louder than the rest by grabbing a 2026 Inc. Power Partner Awards win—for the second year in a row, no less. It seems like they’ve cracked some sort of...